Everything below concerns HGF/c-Met. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-31. Numbers and descriptions here follow the published literature rather than marketing material.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
The boom of Ion exchange chromatography primarily began between 1935 and 1950 during World War II and applications and IC were significantly extended through the Manhattan Project. Ion chromatography was originally introduced by two English researchers, agricultural Sir Thompson and chemist J T Way. The works of Thompson and Way involved the action of water-soluble fertilizer salts, ammonium sulfate and potassium chloride. These salts could not easily be extracted from the ground due to the rain. They performed ion methods to treat clays with the salts, resulting in the extraction of ammonia in addition to the release of calcium. In the 1950s and 1960s, theoretical models were developed for IC for further understanding, and in the 1970s continuous detectors were utilized, paving the path for the development from low-pressure to high-performance chromatography. In 1975, "ion chromatography" was established as a name in reference to the techniques, and was thereafter used as a name for marketing purposes. Today, IC is important for investigating aqueous systems, such as drinking water. It is a popular method for analyzing anionic elements or complexes that help solve environmentally relevant problems. Likewise, it also has great uses in the semiconductor industry. Because of the abundant separating columns, elution systems, and detectors available, chromatography has developed into the main method for ion analysis. When this technique was initially developed, it was primarily used for water treatment.
==== Site selection ==== To prepare for branding a site on the animal's hide must be selected. Careful selection is important for two reasons: first, certain states and counties have various laws regarding legal brand placement and second, the arrangement of muscles beneath the skin determines whether the death of pigment cells occurs evenly. If a brand is attempted in an area that is partly muscle and partly bone the harder bone will take most of the brand while the flexible muscle tissue is less efficiently cooled and so more lightly branded. Modern branding operations are often recorded on video to facilitate the production of records at a later date.
Ni(CO)4 ⇌ Ni + 4 CO This behavior is exploited in the Mond process for purifying nickel. The related nickel(0) complex bis(cyclooctadiene)nickel(0) is a useful catalyst in organonickel chemistry because the cyclooctadiene (or cod) ligands are easily displaced.
Sources: en.wikipedia.org
alternative splicing Also differential splicing or simply splicing. A regulated phenomenon of eukaryotic gene expression in which specific exons or parts of exons from the same primary transcript are variably included within or removed from the final, mature messenger RNA transcript. A class of post-transcriptional modification, alternative splicing allows a single gene to code for multiple protein isoforms and greatly increases the diversity of proteins that can be produced by an individual genome. See also RNA splicing.
The compact structure brings together side groups of amino acids into close enough proximity so that they can interact. When comparing protein structures, as in the SCOP database, core is the region common to most of the structures that share a common fold or that are in the same superfamily. In structure prediction, core is sometimes defined as the arrangement of secondary structures that is likely to be conserved during evolutionary change. Domain (sequence context) a segment of a polypeptide chain that can fold into a three-dimensional structure irrespective of the presence of other segments of the chain. The separate domains of a given protein may interact extensively or may be joined only by a length of polypeptide chain. A protein with several domains may use these domains for functional interactions with different molecules. Family (sequence context) a group of proteins of similar biochemical function that are more than 50% identical when aligned. This same cutoff is still used by the Protein Information Resource (PIR). A protein family comprises proteins with the same function in different organisms (orthologous sequences) but may also include proteins in the same organism (paralogous sequences) derived from gene duplication and rearrangements. If a multiple sequence alignment of a protein family reveals a common level of similarity throughout the lengths of the proteins, PIR refers to the family as a homeomorphic family.
Ruling by decree, the RCC maintained the monarchy's ban on political parties, banned trade unions, and in 1972 outlawed workers' strikes and suspended newspapers. In September 1971, Gaddafi resigned, claiming dissatisfaction with the pace of reform, but returned to his position within a month. In July 1972, amid widespread speculation that Gaddafi had been ousted or jailed by his political opponents, a new 18-man cabinet was formed with only two, Jalloud and Abdel Moneim al-Houni, being military men; the rest were civilian technocrats per Gaddafi's insistence. In February 1973, Gaddafi resigned again, once more returning the next month.
Sources: en.wikipedia.org
=== Medical research relevance === Enzymatic specificity provides useful insight into enzyme structure, which ultimately determines and plays a role in physiological functions. Specificity studies also may provide information of the catalytic mechanism. Specificity is important for novel drug discovery and the field of clinical research, with new drugs being tested for its specificity to the target molecule in various rounds of clinical trials. Drugs must contain as specific as possible structures in order to minimize the possibility of off-target affects that would produce unfavorable symptoms in the patient. Drugs depend on the specificity of the designed molecules and formulations to inhibit particular molecular targets. Novel drug discovery progresses with experiments involving highly specific compounds. For example, the basis that drugs must successfully be proven to accomplish is both the ability to bind the target receptor in the physiological environment with high specificity and also its ability to transduce a signal to produce a favorable biological effect against the sickness or disease that the drug is intended to negate.
=== Academic career === William H. Stein began his higher education as a chemistry major at Harvard University in 1929. He spent one year as a graduate student at Harvard University before transferring to the Department of Biological Chemistry at the College of Physicians and Surgeons, Columbia University, in 1934 to focus on biochemistry. Hans Thatcher Clarke, the chairman of the department at the time, was collecting many talented graduate students who would become the distinguished biochemists of the early twentieth century. In 1937, Stein completed his thesis on the amino acid composition of elastin, earning his Ph.D. Stein was introduced to potassium trioxalatochromate and ammonium rhodanilate by Max Bergmann, a Jewish-German biochemist who fled to the United States in 1934 under threat of Nazi occupation and worked in a laboratory at the Rockefeller Institute. He used these two precipitating agents to isolate the amino acids glycine and proline, respectively, for his research on elastin. With the conclusion of his academic career, Stein went on to work under Bergmann.
== Etymology == The name is derived from "tack", the British sailor slang for food. The earliest use of the term recorded by the Oxford English Dictionary is from 1830. It is known by other names including brewis (possibly a cognate with "brose"), cabin bread, pilot bread, sea biscuit, soda crackers, sea bread (as rations for sailors), ship's biscuit, and pejoratively as dog biscuits, molar breakers, sheet iron, tooth dullers, weevil hardtack, Panzerplatten ("armor plates"; Germany) and worm castles. Australian and New Zealand military personnel knew them with some sarcasm as ANZAC wafers (not to be confused with Anzac biscuit).
The first injector pen, branded "Penject", was introduced in 1983 to administer insulin products, following trials begun in 1981 at Southern General Hospital, Scotland, initiated by Sheila Reith who has conceived the device, and funded by Diabetes UK. The invention was announced, and the preliminary trial described, in a January 1981 paper in The Lancet. The patent rights were later sold to Novo Nordisk by Greater Glasgow Health Board. After their introduction, insulin pens had a slow adoption in the United States, with only 2% of insulin being injected via pen in 1999. A major barrier to adoption in the United States was the increased up-front cost of insulin pens compared to traditional injections. Pen adoption in the United States accelerated after studies showed that the higher up-front cost of insulin pens was offset by the increase in compliance, which decreased overall healthcare costs. Historically, pen needles were manufactured in lengths up to 12.7mm. Over time, pen needles designed for insulin pens have become shorter, and a 4mm long needle is considered sufficient for most people to administer subcutaneously correctly. In 1989, an injector pen form of human growth hormone was licensed in New Zealand.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.